CNS Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $9.8M | $9.3M | $14.1M | $9.3M | $9.8M | $5.1M | $1.9M |
| SG&A Expense | — | $6.2M | $5.6M | $4.8M | $6.0M | $4.7M | $4.4M | $2.0M |
| Operating Income | — | $-16.0M | $-14.9M | $-18.9M | $-15.3M | $-14.5M | $-9.5M | $-3.8M |
| Operating Margin | — | — | — | — | — | — | — | — |
| Interest Expense | — | — | — | $13.8K | $7.0K | $9.3K | $3.3K | $26.2K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | — | $-15.9M | $-14.9M | $-18.9M | $-15.3M | $-14.5M | $-9.5M | $-3.9M |
| Net Margin | — | — | — | — | — | — | — | — |
| EPS (Basic) | — | $-35.75 | $-33.35 | $-893.51 | $-0.27 | $-0.39 | $-0.01 | $-0.01 |
| EPS (Diluted) | — | $-35.75 | $-33.35 | $-893.51 | $-0.27 | $-0.39 | $-0.01 | $-0.01 |
| Shares Outstanding (Basic) | 811.4K | 443.4K | 445.5K | 52.7M | 57.2M | 36.9M | 1.00B | 690.9M |
| Shares Outstanding (Diluted) | 811.4K | 443.4K | 445.5K | 52.7M | 57.2M | 36.9M | 1.00B | 690.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |